Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
HONG KONG, Apr 8, 2026 – (ACN Newswire via SeaPRwire.com) – Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in 2025 and kicked off its international expansion, as the Phase III clinical trial of bevacizumab met its primary endpoint and Beifushu® was successfully introduced […]













